NO842260L - Stabilisert produkt for koaguleringsregulering - Google Patents

Stabilisert produkt for koaguleringsregulering

Info

Publication number: NO842260L
Authority: NO; Norway
Prior art keywords: water; group; net; reagent; plasma
Prior art date: 1983-06-06

Application number

NO842260A

Other languages

English (en)

Norwegian (no)

Inventor

Michael Kevin Hoskins

Original Assignee

Ortho Diagnostic Systems Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-06

Filing date

1984-06-05

Publication date

1984-12-07

1984-06-05 Application filed by Ortho Diagnostic Systems Inc filed Critical Ortho Diagnostic Systems Inc

1984-12-07 Publication of NO842260L publication Critical patent/NO842260L/no

Links

230000015271 coagulation Effects 0.000 title claims description 29
238000005345 coagulation Methods 0.000 title claims description 29
239000003153 chemical reaction reagent Substances 0.000 claims description 56
238000000034 method Methods 0.000 claims description 34
239000003381 stabilizer Substances 0.000 claims description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
238000012360 testing method Methods 0.000 claims description 22
239000003146 anticoagulant agent Substances 0.000 claims description 19
229940127219 anticoagulant drug Drugs 0.000 claims description 19
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
235000000346 sugar Nutrition 0.000 claims description 12
238000004108 freeze drying Methods 0.000 claims description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
230000035602 clotting Effects 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 10
229960002897 heparin Drugs 0.000 claims description 10
229920000669 heparin Polymers 0.000 claims description 10
239000008101 lactose Substances 0.000 claims description 10
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 9
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
206010053567 Coagulopathies Diseases 0.000 claims description 9
102000009123 Fibrin Human genes 0.000 claims description 9
108010073385 Fibrin Proteins 0.000 claims description 9
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 9
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 9
239000003114 blood coagulation factor Substances 0.000 claims description 9
229950003499 fibrin Drugs 0.000 claims description 9
-1 monosaccharide sugars Chemical class 0.000 claims description 9
108010054218 Factor VIII Proteins 0.000 claims description 7
102000001690 Factor VIII Human genes 0.000 claims description 7
108090000783 Renin Proteins 0.000 claims description 7
102100028255 Renin Human genes 0.000 claims description 7
229960000301 factor viii Drugs 0.000 claims description 7
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
229930195725 Mannitol Natural products 0.000 claims description 6
229930006000 Sucrose Natural products 0.000 claims description 6
239000000594 mannitol Substances 0.000 claims description 6
235000010355 mannitol Nutrition 0.000 claims description 6
239000005720 sucrose Substances 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
108010064733 Angiotensins Proteins 0.000 claims description 4
102000015427 Angiotensins Human genes 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
125000000185 sucrose group Chemical group 0.000 claims description 4
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
238000001816 cooling Methods 0.000 claims description 3
125000003071 maltose group Chemical group 0.000 claims description 3
238000002481 ethanol extraction Methods 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
238000002360 preparation method Methods 0.000 claims 2
235000004443 Ricinus communis Nutrition 0.000 claims 1
125000001547 cellobiose group Chemical group 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
230000006641 stabilisation Effects 0.000 claims 1
238000011105 stabilization Methods 0.000 claims 1
150000008163 sugars Chemical class 0.000 claims 1
239000000463 material Substances 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000000047 product Substances 0.000 description 5
230000007812 deficiency Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
102100022641 Coagulation factor IX Human genes 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 2
108010080865 Factor XII Proteins 0.000 description 2
102000000429 Factor XII Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
229960002478 aldosterone Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000006624 extrinsic pathway Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
206010047634 Vitamin K deficiency Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000007820 coagulation assay Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000005496 eutectics Effects 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
208000009429 hemophilia B Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
XJFQCYIFOWHHFN-PLKCGDGVSA-N hypertensinogen Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 XJFQCYIFOWHHFN-PLKCGDGVSA-N 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000006623 intrinsic pathway Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940127216 oral anticoagulant drug Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
150000003267 reducing disaccharides Chemical class 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
229940108461 rennet Drugs 0.000 description 1
108010058314 rennet Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)
Compounds Of Unknown Constitution (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO842260A 1983-06-06 1984-06-05 Stabilisert produkt for koaguleringsregulering NO842260L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US50121683A	1983-06-06	1983-06-06

Publications (1)

Publication Number	Publication Date
NO842260L true NO842260L (no)	1984-12-07

Family

ID=23992589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO842260A NO842260L (no)	1983-06-06	1984-06-05	Stabilisert produkt for koaguleringsregulering

Country Status (6)

Country	Link
JP (2)	JPS6018762A (ja)
AU (1)	AU584859B2 (ja)
CA (1)	CA1226795A (ja)
DK (1)	DK275384A (ja)
IL (1)	IL72032A0 (ja)
NO (1)	NO842260L (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1226795A (en) *	1983-06-06	1987-09-15	Michael K. Hoskins	Stabilized coagulation control products
CA1230300A (en) *	1983-06-06	1987-12-15	Michael K. Hoskins	Stabilized isoenzyme control product
CA1226794A (en) *	1983-06-06	1987-09-15	Michael K. Hoskins	Stabilized multiparameter control product
US4663295A (en) *	1983-06-29	1987-05-05	Ciba Corning Diagnostics Corp.	Estrogen-progesterone control reagents and methods for making same
JPH0695092B2 (ja) *	1989-10-30	1994-11-24	隆己永田	血球計数用抗凝固剤
WO2004046723A1 (ja) *	2002-11-18	2004-06-03	Denka Seiken Co., Ltd.	血清および血漿の測定値乖離を防止する免疫測定法
US7588942B2 (en) *	2006-08-04	2009-09-15	Bio-Rad Laboratories, Inc.	Standard/reference/control for blood coagulation testing
EP2405275B1 (en)	2009-03-05	2018-10-10	BML, Inc.	Method for measuring glycated albumin contained in serum or plasma using mannitol as stabiliser for a control serum or plasma.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2461969A1 (de) *	1974-12-31	1976-07-08	Behringwerke Ag	Stabiles blutplasma, verfahren zu dessen herstellung und seine verwendung als vergleichsplasma bei gerinnungs- untersuchungen
JPS5757661A (en) *	1980-09-25	1982-04-06	Daicel Ltd	Film for separately packing sliced cheese
CA1226795A (en) *	1983-06-06	1987-09-15	Michael K. Hoskins	Stabilized coagulation control products
CA1230300A (en) *	1983-06-06	1987-12-15	Michael K. Hoskins	Stabilized isoenzyme control product
CA1226794A (en) *	1983-06-06	1987-09-15	Michael K. Hoskins	Stabilized multiparameter control product
JPH0511264A (ja) *	1991-07-05	1993-01-19	Hitachi Ltd	液晶表示装置

1984
- 1984-05-25 CA CA000455086A patent/CA1226795A/en not_active Expired
- 1984-06-04 DK DK275384A patent/DK275384A/da not_active Application Discontinuation
- 1984-06-04 JP JP11322684A patent/JPS6018762A/ja active Granted
- 1984-06-05 IL IL72032A patent/IL72032A0/xx unknown
- 1984-06-05 AU AU29086/84A patent/AU584859B2/en not_active Ceased
- 1984-06-05 NO NO842260A patent/NO842260L/no unknown
1991
- 1991-12-10 JP JP34986791A patent/JPH0560753A/ja active Pending

Also Published As

Publication number	Publication date
AU584859B2 (en)	1989-06-08
IL72032A0 (en)	1984-10-31
DK275384D0 (da)	1984-06-04
DK275384A (da)	1984-12-07
JPH0560753A (ja)	1993-03-12
JPH0511264B2 (ja)	1993-02-15
CA1226795A (en)	1987-09-15
JPS6018762A (ja)	1985-01-30
AU2908684A (en)	1984-12-13

Publication	Publication Date	Title
JP2828837B2 (ja)	1998-11-25	トロンボプラスチン抽出物、試薬およびそれらの調製方法
Al-Mondhiry et al.	1975	Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation
Quick et al.	1949	The prothrombin consumption test: its clinical and theoretic implications
Aadland et al.	1992	Free protein S deficiency in patients with chronic inflammatory bowel disease
CA1330302C (en)	1994-06-21	Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
NO842260L (no)	1984-12-07	Stabilisert produkt for koaguleringsregulering
Dolan et al.	1988	Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds
CN109082458B (zh)	2024-02-23	一种血栓弹力图法定量检测口服凝血因子Xa抑制剂试剂盒及其制备方法
DIDISHEIM	1962	Hageman factor deficiency (Hageman trait): case report and review of the literature
Knöfler et al.	1998	Molecular markers of the endothelium, the coagulation and the fibrinolytic systems in healthy newborns
EP0130708A1 (en)	1985-01-09	Stabilized clinical control reagents
Mari et al.	1981	Hemostasis and liver disease
NO161079B (no)	1989-03-20	Reagens for optisk bestemmelse av blodkoaguleringsforholdet.
Becketta et al.	1985	Plasma glutathione S-transferase measurements by radioimmunoassay: a sensitive index of hepatocellular damage in man
Outryve et al.	1973	Antmaemophilic Factor A (F VIII) and Serum Fibrin‐Fibrinogen Degradation Products in Hepatic Cirrhosis
CN112557665B (zh)	2023-06-09	一种狼疮抗凝物的确认试剂及其制备方法
EP2405274A1 (en)	2012-01-11	Monitoring anticoagulant therapy and identifying reversible direct factor Xa inhibitors
Angelos et al.	1986	Coagulation studies: prothrombin time, partial thromboplastin time, bleeding time
Poller	1960	The pathogenesis of thrombosis
JP2996517B2 (ja)	2000-01-11	採血容器
CN112433057B (zh)	2023-06-09	一种狼疮抗凝物的筛选试剂及其制备方法
Almér et al.	1975	Fibrinolysis in relation to circulation through the legs in diabetics
Nighoghossian et al.	1994	Free protein S spectrum in young patients with stroke
DANN et al.	1958	Congenital serum prothrombin conversion accelerator (SPCA) deficiency
Condie	1976	Plasma Fibrinolytic Activity in Pregnancy with Particular Reference to Pre‐eclampsia